Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial - Rocket Pharm

Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.

Raccontata dabenzinga.com